
⚠ COVID-19 INFORMATION: Resources, Vaccine Information
The primary objectives of this study are to evaluate the safety, tolerability, and pharmacokinetics (PK) of remdesivir (RDV) in participants with laboratory-confirmed coronavirus disease 2019 (COVID-19) aged 0 days to < 18 years.
Laura Fearn, RN
Research Nurse
312.227.6285